Get the Stockscreener App
12.39
1.27%
-0.16
After Hours:
12.38
-0.010
-0.08%
Fennec Pharmaceuticals Inc stock is traded at $12.39, with a volume of 212.44K.
It is down -1.27% in the last 24 hours and up +22.55% over the past month.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.
See More
Previous Close:
$12.55
Open:
$12.45
24h Volume:
212.44K
Relative Volume:
0.93
Market Cap:
$434.48M
Revenue:
$51.00M
Net Income/Loss:
$-8.73M
P/E Ratio:
-41.83
EPS:
-0.2962
Net Cash Flow:
$-7.75M
1W Performance:
+0.98%
1M Performance:
+22.55%
6M Performance:
+51.10%
1Y Performance:
+34.97%
1-Day Range:
$12.29
$12.60
1-Week Range:
$11.87
$12.79
52-Week Range:
$5.65
$13.25
Fennec Pharmaceuticals Inc Stock (FENC) Company Profile
Name
Fennec Pharmaceuticals Inc
Sector
Industry
Phone
(919) 636-4530
Address
PO BOX 13628, RESEARCH TRIANGLE PARK, NC
Compare FENC vs VRTX, REGN, ARGX, MRNA, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
FENC
Fennec Pharmaceuticals Inc
|
12.39 | 398.01M | 51.00M | -8.73M | -7.75M | -0.2962 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Fennec Pharmaceuticals Inc Stock (FENC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-12-26 | Initiated | B. Riley Securities | Buy |
| Jan-09-26 | Initiated | Piper Sandler | Overweight |
| Nov-22-22 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Sep-07-22 | Initiated | CapitalOne | Overweight |
| Aug-08-22 | Resumed | Craig Hallum | Buy |
| Jun-05-20 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-11-18 | Initiated | Goldman | Buy |
View All
Fennec Pharmaceuticals Inc Stock (FENC) Latest News
(FENC) Risk Channels and Responsive Allocation - news.stocktradersdaily.com
Fennec Pharmaceuticals Stock Price Forecast. Should You Buy FRX.TO? - StockInvest.us
What's Going On With Fennec Pharmaceuticals Inc Stock Thursday? - Wealth Awesome
Fennec Pharmaceuticals Insider Rosty Raykov Reports Share Vesting and Sale - Kalkine Media
Former Fennec (NASDAQ: FENC) director lines up $121K stock sale - Stock Titan
Former Fennec Pharma (NASDAQ: FENC) director sells 10,000 shares under 10b5-1 plan - Stock Titan
Fennec (NASDAQ: FENC) CMO sells 12,000 vested shares in an August 31 trade not tied to a preset Rule 10b5-1 plan. - Stock Titan
156 previously restricted Fennec Pharma (FENC) shares are released to the chief strategy officer at a stated $0.00 per share. - Stock Titan
Fennec Pharma (NASDAQ: FENC) officer to sell 12,000 shares - Stock Titan
Trade Alert: Chief Financial Officer Of Fennec Pharmaceuticals Robert Andrade Has Sold Stock - webull.com
Fennec Pharma (NASDAQ: FENC) CFO sells 75K shares in plan trade - Stock Titan
Fennec Pharma (NASDAQ: FENC) officer to sell 75,000 shares - Stock Titan
Fennec Pharmaceuticals Inc. Revenue Breakdown – NASDAQ:FENC - TradingView
Fennec (FENC) Results Review: Reported EPS Tops Expectations in the Latest Reading; Share Response: The Share Price Sheds 4.63% at the CloseEPS Estimate Trend - vinanet.vn
Fennec (FENC) Results Check: Profit Per Share Clears Its Benchmark on the Day; Investor Response - vinanet.vn
Fennec (FENC) Technical Check: Adds 0.51% to Close at $11.89 at the Close; Current Setup: the Supplied Trading Band Runs From $11.30 to $12.48Throwback Trade - vinanet.vn
Jessica Vargas Appointed Vice President of Human Resources at Fennec Pharmaceuticals - hrtoday.in
(FENC) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Fennec Pharmaceuticals (FENC): Southpoint group files 13G/A showing 0% ownership - Stock Titan
Fennec Pharmaceuticals (FENC) Gets a Buy from Maxim Group - The Globe and Mail
Solas Capital Management (FENC) reports 1.89M Fennec shares, a 5.4% ownership stake - Stock Titan
Results: Fennec Pharmaceuticals Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates - Moomoo
Results: Fennec Pharmaceuticals Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts - simplywall.st
Fennec Pharmaceuticals (FENC) Stock Sees Fair Value Lift As Analysts Raise PEDMARK Views - Yahoo Finance
Fennec Pharmaceuticals Announces Q2 2026 Net Income and Revenue Growth - Kalkine Media
Fennec Pharmaceuticals (FENC) Stock Jumps As Profitability Raises A Bigger Question - webull.com
Fennec Pharmaceuticals (FENC) gains 9.6% stakeholder via Rosalind Advisors - Stock Titan
Fennec Pharmaceuticals (FENC) Gets a Buy from Wedbush - The Globe and Mail
Why Fennec Pharmaceuticals Inc stock plummeted yesterday - Wealth Awesome
B. Riley Financial Reaffirms "Buy" Rating for Adherex Technologies (NASDAQ:FENC) - MarketBeat
Wedbush Boosts Adherex Technologies (NASDAQ:FENC) Price Target to $16.00 - MarketBeat
Fennec: The Turnaround Is Real, But The Stock Prices In Perfection (Downgrade) - Seeking Alpha
Why Fennec Pharmaceuticals Inc stock surged yesterday - Wealth Awesome
B. Riley Adjusts Fennec Pharmaceuticals Price Target to $18 From $16, Maintains Buy Rating - marketscreener.com
Fennec Pharmaceuticals Inc FRX Earnings Beat Estimates by 248.5% - Wealth Awesome
Adherex Technologies Q2 2026 Earnings Call Transcript - MarketBeat
Fennec Pharmaceuticals Inc. Stock 12‑Month Price Target Raised to $16.17, Implies 48% Upside - TradingView
Fennec Pharmaceuticals Inc (FENC) (Q2 2026) Earnings Call Highlights: Record Sales and ... - Yahoo Finance
Fennec Pharmaceuticals Releases Q2 2026 Financial Results - AlphaStreet
Adherex Technologies Q2 Earnings Call Highlights - newsbreak.com
Fennec Pharmaceuticals at Multi-Year High After Swing to Q2 Earnings Beat - marketscreener.com
Adherex Technologies (NASDAQ:FENC) Announces Earnings Results, Beats Estimates By $0.03 EPS - MarketBeat
Fennec Pharmaceuticals surges 8% as Q2 earnings and revenue beat estimates - Yahoo Finance
Transcript : Fennec Pharmaceuticals Inc., Q2 2026 Earnings Call, Aug 11, 2026 - marketscreener.com
Fennec Pharmaceuticals Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Fennec Pharmaceuticals posts second quarter results and issues business update - tradersunion.com
Fennec Pharmaceuticals surges 8% on Q2 earnings, revenue beat By Investing.com - Investing.com Nigeria
Fennec Pharmaceuticals surges 8% on Q2 earnings, revenue beat - Investing.com
FENNEC PHARMACEUTICALS ($FENC) Releases Q2 2026 Earnings - Quiver Quantitative
Fennec Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update - The Manila Times
FENC: Q2 2026 sales surged 78% year-over-year, with profitability and strong PEDMARKⓇ demand - TradingView
Fennec Pharmaceuticals Inc Stock (FENC) Financials Data
Revenue
Net Income
Cash Flow
EPS
Fennec Pharmaceuticals Inc Stock (FENC) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Raykov Rosty | Former Director |
Sep 01 '26 |
Sale |
12.11 |
10,000 |
121,100 |
124,411 |
| Sayad Pierre Sargis | Chief Medical Officer |
Aug 31 '26 |
Sale |
12.18 |
12,000 |
146,160 |
9,519 |
0.86%
0.31%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):